Skip to content

Released Mar 27, 2026, before the open

10-K filed Mar 27, 2026, 86 days after period end · 0001785530-26-000006

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$8.38MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$9,418,000N/M
Operating Cash Flowderived-$11,024,000N/M
Free Cash Flowderived-$11,024,000N/M

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Net Income-$8.38M-$20.40M-$12.00M-$11.93M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR